NewsBenzingaRaymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42 Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42 Benzinga 2026.10.09 11:01 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says